C Diff Treatment

A gastroenterologist reviews long-term impact of dysbiosis and C. difficile infection (CDI).

DEINOVE présente des données sur #DNV3837 au congrès ESCMID/ASM à Dublin. L'utilisation du DNV3837 est un changement de paradigme potentiel pour le traitement de l'infection par #CDiff permettant de traiter l’intestin dans son ensemble.https://t.co/QFH7TOZ2me pic.twitter.com/u2DQJEwc7E— Deinove (@Deinove) October 5, 2022

#Cdiff 2nd recurrence, after Po Vanco (initial), then Po fidaxomicin (1st recurrence). No bezlotoxumab. What to give on 2nd recurrence?— Ricardo Cedeno-Mendoza, MD (@ricardocedenomd) October 4, 2022

Ulcerative colitis is a chronic debilitating inflammatory bowel disease with no curative treatment currently available. INRAE scientists have developed a novel predictive model of disease progression in pediatric patients that integrates both gut microbiota and host inflammation data.

In terms of clinical cure rates and adverse event rates in Clostridioides difficile infection (CDI) patients, fidaxomicin (FDX) is equivalent to vancomycin (VCM) and yields noticeably greater...

Clostridioides difficile infection (CDI) remains a devastating infection both in hospital settings and in the community. While a number of antibiotics have anti-C. difficile activity, fidaxomicin is unique as a minimally absorbed antibiotic with narrow spectrum of activity. These featu …

Researchers assessed whether fidaxomicin is superior to vancomycin in patients with C difficile infection.

Not sure what is the best advice you can offer to your patients in terms of fixing gut-related issues? This infographic summarizes what works based on sound science: pic.twitter.com/BghKOLgyfS— GutMicrobiota Health (@GMFHx) September 30, 2022

The closely related terms “fiber”, “microbiota-accessible carbohydrates” (or MACs) and “prebiotics” probably sound familiar. But what exactly are they and how can they contribute to promoting health and abrogating disease by shaping the gut microbiome? https://t.co/4onLUef1Ev— GutMicrobiota Health (@GMFHx) September 27, 2022

Initial vancomycin was associated with a reduced rate of new incident infection in the treatment of adult inpatients with first-episode non-severe CDI. These findings support the use of initial vancomycin for all inpatients with CDI, when fidaxomicin is unavailable.

Are you ready to attend the next @esnm_eu webinar on the management of recurrence of C. difficile infection?🗣 Daniel Pohl, Steven Johnson & Tariq Iqbal.👉 Join us on 12th October: https://t.co/GUYnBtIJOc pic.twitter.com/HdNsXTRYVw— GutMicrobiota Health (@GMFHx) September 28, 2022

Now at #LDDC22 at @ECCLeiden ; come to the sesssion on the Future of Anti-Infectives to hear my perspective on the future of #cdiff therapeutics @cdiffFoundation @Leidenbsp https://t.co/ViXCpEWS7k— Wiep Klaas Smits (@SmitsLab) September 27, 2022

Inflammatory bowel disease (IBD) patients are particularly vulnerable to infection with Clostridium difficile infection (CDI).Available treatments of IBD with CDI have not effective. Butyrate, the metabolites of microbiota, plays a vital role in maintaining immune homeostasis and potential drugs for …

Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an emphasis on rapid restoration of the gut microbiot …

“@HannahMeekID22 Had yet another patient today that couldnt afford #fidaxomicin on discharge... I hope GI and ID are practicing in the real 🌎 and not based on society guidelines that may not be able to be translated into clinical practice thanks to drug cost. #IDtwitter #cdiff”

Oral Fidaxomicin Versus Vancomycin for Clostridioides difficile Infection

“The #cdiff #vancomycin vs #fidaxomicin topic continues onward! (I mean, who still uses Flagyl first line..? The studies the guidelines are based on don’t REALLY assess the mild diseases though…) #IDTwitter #MedTwitter #MedEd #idcrit”

Clostridioides difficile infection (CDI) has a higher incidence in solid organ transplant recipients than other hospitalized patients and can lead to poor outcomes. Perturbations to the intestinal microbiome are common in patients undergoing liver transplant (LT); however, the impacts of microbial d …

Clostridioides difficile infection is closely related to the intestinal flora disorders induced by antibiotics, and changes in the intestinal flora may cause the occurrence and development of Clostridioides difficile infection. Epigallocatechin-3-gallate (EGCG) is one of the major bioa …

We describe the epidemiology of C. difficile infections (CDIs) focused on treatment and analyze the risk factors for mortality. This is a retrospective cohort study of CDI cases with a positive A/B toxin in the stool in 2017-2018. We analyzed the demographic data, comorbidities, previous use …

Clostridioides difficile infections (CDIs), and particularly recurrent infections, cause a significant burden on the health-care system. Bezlotoxumab is a new agent for the prevention of recurrent CDIs that has shown strong efficacy and high tolerability in clinical trials. The purpose of thi …

Identifying the clinical evidence for safety and efficacy of fidaxomicin for pediatric Clostridiodes difficile infection. Read more

Clostridioides difficile infection (CDI) disproportionately affects certain populations, but few studies have investigated health outcome disparities among patients with CDI. This study aimed to characterize CDI treatment and health outcomes among patients by age group, sex, race, and ethnici …

In 2021, the American College of Gastroenterology (ACG), the Infectious Diseases Society of America in conjunction with the Society for Healthcare Epidemiology of America (IDSA/SHEA), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published updated clinical practi …

Are you ready to attend the next @esnm_eu webinar on the management of recurrence of C. difficile infection?🗣 Daniel Pohl, Steven Johnson & Tariq Iqbal.👉 Join us on 12th October: https://t.co/GUYnBtJhDK pic.twitter.com/7DXTXDBzTg— GutMicrobiota Health (@GMFHx) September 21, 2022

Mark your calendars: on Oct 4th @simone_s_li , @DanielPodlesny , @NicolaiKarcher & I will do an #AMA on @RedditAskSci on the #microbiome and #FMT (Fecal Microbiota Transplantation).We'll discuss our 3 recent studies & look forward to your questions!1/5— Sebastian Schmidt (@TSBSchm) September 21, 2022

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Infliximab led to complete resolution of symptoms in 73% of patients with IMC. High prednisolone dose at tapering was associated with increased mortality rate and a high incidence of infections and hospitalisations in patients with severe IMC. We suggest optimised infliximab treatment before escalat …

Clostridium difficile infection (CDI) is the most common nosocomial infection in hospitals. Despite the fact that CDI has treatment options, recurrence is common after the treatment, recurrence will occur in approximately 20%-35% of people initially affected, with 40%-60% of these having a second re …

Annals for Hospitalists Inpatient Notes - Clinical Pearls-Updates on Clostridioides difficile Infection for Hospitalists